KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Petmed Express (PETS) Cash & Equivalents (2016 - 2025)

Petmed Express has reported Cash & Equivalents over the past 16 years, most recently at $26.9 million for Q4 2025.

  • For Q4 2025, Cash & Equivalents fell 46.28% year-over-year to $26.9 million; the TTM value through Dec 2025 reached $26.9 million, down 46.28%, while the annual FY2025 figure was $54.7 million, 1.05% down from the prior year.
  • Cash & Equivalents for Q4 2025 was $26.9 million at Petmed Express, down from $36.1 million in the prior quarter.
  • Over five years, Cash & Equivalents peaked at $118.7 million in Q1 2021 and troughed at $26.9 million in Q4 2025.
  • A 5-year average of $74.6 million and a median of $58.4 million in 2023 define the central range for Cash & Equivalents.
  • Biggest five-year swings in Cash & Equivalents: rose 28.79% in 2021 and later tumbled 51.77% in 2023.
  • Year by year, Cash & Equivalents stood at $108.9 million in 2021, then decreased by 5.95% to $102.4 million in 2022, then tumbled by 51.77% to $49.4 million in 2023, then increased by 1.42% to $50.1 million in 2024, then crashed by 46.28% to $26.9 million in 2025.
  • Business Quant data shows Cash & Equivalents for PETS at $26.9 million in Q4 2025, $36.1 million in Q3 2025, and $41.1 million in Q2 2025.